Skip to content

A prospective real - world clinical study on the use of Reduning Injection for the prevention of sepsis in high - risk populations with respiratory system infections

A prospective real - world clinical study on the use of Reduning Injection for the prevention of sepsis in high - risk populations with respiratory system infections

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600132244
Enrollment
Unknown
Registered
2026-09-11
Start date
2026-09-11
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory infections

Interventions

Conventional Treatment plus Reduning Injection:None

Sponsors

The First People’s Hospital of Lianyungang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Meet diagnostic criteria for acute upper respiratory infection, acute tracheobronchitis, or pulmonary infection and fulfill the definition of high-risk population. 2.Age =18 years, no gender restriction. 3.Symptom duration limits: Acute upper respiratory infection: =48 hours Acute bronchitis: =72 hours Pulmonary infection: =72 hours after diagnosis. 4.Provide informed consent with signed documentation.

Exclusion criteria

Exclusion criteria: 1.Prior use of traditional Chinese medicine (including herbal decoctions, proprietary Chinese medicines, or hospital-prepared formulations) since current illness onset. 2.Participation in any clinical trial within 1 month prior to enrollment. 3.Pregnant women, women planning pregnancy within 1 month, or lactating women. 4.Allergic constitution (e.g., history of allergy to =2 medications/foods) or known hypersensitivity to Reduning Injection or its components. 5.Deemed unsuitable for the study by the investigator’s judgment.

Design outcomes

Primary

MeasureTime frame
Proportion of Participants Progressing to Sepsis or Septic Shock Within 14 Days;

Secondary

MeasureTime frame
Changes in vital signs (axillary temperature, respiratory rate, pulse, blood pressure [systolic/diastolic]);All-cause mortality within 28 days;Change from baseline in APACHE II score;Proportion of participants hospitalized within 28 days and length of hospital stay during the 28-day period.;Adverse Event (AE) / Serious Adverse Event (SAE);12-lead resting electrocardiogram (ECG) data;Change from baseline in SOFA score;Laboratory abnormalities (CBC, LFTs/RFTs, ABG, electrolytes, urinalysis) graded per CTCAE v6.0.;Change from baseline in NEWS2 score;

Countries

China

Contacts

Public ContactLi Xiaomin, Xie Yongpeng

The First People’s Hospital of Lianyungang

18961325327@163.com+86 518 85767003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026